GenoMed's Dr. David Moskowitz Featured on Wall Street Reporter; Says GenoMed Set to Improve Nation's Public Health
March 24, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that its Chairman and CEO, Dr. David Moskowitz, is featured in Wall Street Reporter Magazine discussing how preventive molecular medicine as GenoMed practices it can significantly lower healthcare costs.
wallstreetreporter.com
GenoMed also participated in a recent Genomics Roundtable hosted by the Wall Street Reporter Magazine, available at:
wallstreetreporter.com
GenoMed has aligned its business model with optimizing public health. The Company's goal is to find the least expensive, fastest, and safest way to improve patient outcomes. The Company has already accomplished this for diabetes, hypertension, and emphysema, which affect over 85 million Americans. This summer GenoMed will again conduct a free national trial for West Nile virus using already existing, FDA-approved drugs.
GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's) and Consumer-Directed Health Care (CDHC). In addition to educating health plans about its Next Generation DM(tm) services, GenoMed is also encouraging patients who control their own Health Savings Account to sign up themselves for GenoMed's modestly priced services.
About GenoMed
GenoMed has already found what it believes is the major gene for aging. Using this information, GenoMed has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics, dramatically delay the progression of terminal emphysema, and treat autoimmune diseases and cancer. GenoMed has recently found several thousand genes for the top six solid cancers--breast, colon, lung, ovarian, pancreatic, and prostate--and expects to have new diagnostic and therapeutic tools ready for clincal trials soon.
. |
